Fall 2011 - Innovation

Baxter Receives FDA Approval for Gammagard Liquid

Baxter International has received U.S. Food and Drug Administration approval for subcutaneous administration of Gammagard Liquid 10% (immune globulin infusion [human]) for patients with primary immunodeficiency. According to Richard Schiff, Baxter’s gammaglobulin trials medical director, “Building upon years of strong clinical data of Gammagard Liquid, our subcutaneous clinical trial in patients with PI demonstrated efficacy consistent with that seen in other clinical studies of intravenous and subcutaneous immune globulin.” Gammagard Liquid is indicated as replacement therapy for primary humoral immunodeficiency in adult and pediatric patients 2 years of age and older.

BSTQ Staff
BioSupply Trends Quarterly [BSTQ] is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace. With timely and critical information, each themed issue covers topics ranging from product breakthroughs, industry insights and innovations, up-to-the-minute news on the latest clinical trials, accessibility, and service and safety concerns.